FDA Sniffs Asthma Drugs Over Child Safety Concerns

Law360, New York (November 26, 2007, 12:00 AM EST) -- Safety officials at the Food and Drug Administration will meet this week to discuss the rare, but potentially fatal, side effects of GlaxoSmithKline Plc's top-selling asthma drugs Serevent and Advair in children.

The advisory panel, which will meet from Tuesday to Thursday of this week, comes after a scathing October report in which FDA staff concluded that the two asthma medications, as well as Novartis' Foradil, may have “an unfavorable risk-benefit ratio” for children's asthma.

The drugs contain the active ingredient salmeterol which may cause adverse...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.